NIH R01 · 2025
Nucleoside-modified mRNA vaccine for prevention and treatment of genital herpes
Abstract Genital herpes affects 650 million people globally. Vaccines are urgently needed to prevent infection and treat individuals already infected. During the current funding cycle, we developed a candidate vaccine for preventing genital herpes that uses nucleoside-modified mRNA encapsulated within lipid nanoparticles (LNP) to express herpes simplex virus type 2 (HSV-2) glycoproteins C, D, and E (gC2, gD2, gE2). The vaccine targets an entry molecule, gD2, and two immune evasion molecules, gC2 and gE2. Our vaccine candidate will enter phase 1 human trials in December 2022. Our new goals are to define the immune correlates of protection for the trivalent vaccine using sera we collected…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.